Literature DB >> 3429387

An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin.

R Anderson1, C E Van Rensburg, G Jooné, P T Lukey.   

Abstract

The binding to human polymorphonuclear leucocytes and the intracellular bioactivity of the macrolide antibiotics erythromycin and roxithromycin on Legionella micdadei, Listeria monocytogenes and Staphylococcus aureus were investigated in vitro by the combination of a fluorochrome microassay and a radioassay. Polymorphs with intact or absent membrane-associated oxidative metabolism were used to investigate the interactions which may occur between the intrinsic oxygen-dependent antimicrobial systems of human polymorphs and the test antibiotics, in the elimination of intracellular microbial pathogens. Elimination of O2-dependent antimicrobial systems with retention of phagocytic activity was achieved by using polymorphs from children with chronic granulomatous disease NaF-pulsed normal polymorphs. Both antimicrobial agents were actively concentrated by polymorphs. Erythromycin was concentrated ten-fold and roxithromycin approximately thirty-fold above extra cellular levels. Both agents possessed intracellular bacteriostatic activity for all three test microbial pathogens. Depletion of polymorph O2-dependent intrinsic antimicrobial systems interfered with the intracellular bioactivity of both antibiotics. This emphasizes the importance of interactions between cell-associated antibiotics and phagocyte antimicrobial systems in the elimination of intracellular microbial pathogens. Like erythromycin, roxithromycin is concentrated by human phagocytes and is bioactive intracellularly.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3429387     DOI: 10.1093/jac/20.suppl_b.57

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells.

Authors:  T Fujii; J Kadota; T Morikawa; Y Matsubara; K Kawakami; K Iida; R Shirai; H Taniguchi; M Kaseda; S Kawamoto; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Intraphagocytic activity of erythromycin, roxithromycin and azithromycin.

Authors:  D Milatovic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

3.  Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin.

Authors:  D Vazifeh; H Abdelghaffar; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils.

Authors:  R Anderson; A J Theron; C Feldman
Journal:  Inflammation       Date:  1996-12       Impact factor: 4.092

Review 5.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 6.  Clarithromycin clinical pharmacokinetics.

Authors:  F Fraschini; F Scaglione; G Demartini
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

7.  Effects of dirithromycin and erythromycylamine on human neutrophil degranulation.

Authors:  H Abdelghaffar; E M Mtairag; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Clindamycin, erythromycin, and roxithromycin inhibit the proinflammatory interactions of Pseudomonas aeruginosa pigments with human neutrophils in vitro.

Authors:  G J Ras; R Anderson; G W Taylor; J E Savage; E van Niekerk; G Joone; H J Koornhof; J Saunders; R Wilson; P J Cole
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  Azithromycin inhibition of intracellular Legionella micdadei.

Authors:  G R Donowitz; K I Earnhardt
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

Review 10.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.